We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sofosbuvir Off-label Treatment of Yellow Fever Patients During an Outbreak in Brazil, 2018: A Cohort Study.
- Authors
Rezende, Izabela M; Mendonça, Diogo Correa; Costa, Thais Alkifeles; Oliveria, Gabriela Fernanda Garcia de; Arruda, Matheus Soares; Gonçalves, Andreza Parreiras; Alves, Pedro Augusto; Calzavara-Silva, Carlos Eduardo; Martins-Filho, Olindo A; Teixeira-Carvalho, Andréa; Bonjardim, Claudio Antonio; Monath, Thomas P; LaBeaud, A Desiree; Drumond, Betânia P; Pascoal-Xavier, Marcelo Antônio; Pereira, Leonardo S; Ramalho, Dario Brock
- Abstract
We enrolled 21 patients with laboratory-confirmed yellow fever (YF), hospitalized at Eduardo de Menezes Hospital, Brazil, to be treated with sofosbuvir, a drug approved for hepatitis C. Given the absence of specific YF antiviral treatments, the off-label nonrandomized sofosbuvir treatment aimed to address high disease severity and the risk of fatal outcomes. Patients received a daily dose of 400 mg sofosbuvir from 4 to 10 days post–symptom onset. YF viral load (VL) comparisons were made between treated and nontreated patients who either survived or died. The genomic VL for the treated group steadily decreased after day 7 post–symptom onset, suggesting that sofosbuvir might reduce YF VL. This study underscores the urgent need for YF antiviral therapies, advocating for randomized clinical trials to further explore sofosbuvir's role in YF treatment.
- Subjects
BRAZIL; YELLOW fever; SOFOSBUVIR; CLINICAL trials; COHORT analysis; VIRAL load; Q fever
- Publication
Open Forum Infectious Diseases, 2024, Vol 11, Issue 6, p1
- ISSN
2328-8957
- Publication type
Article
- DOI
10.1093/ofid/ofae312